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Abstract The traditional Mediterranean diet (MedDiet)
has shown beneficial effects on cognitive decline. Never-
theless, diet–gene interactions have been poorly evaluated.
We aimed to investigate diet–gene interaction in the
PREDIMED-NAVARRA randomized trial. A total of 522
participants (67 ± 6 years at baseline) enrolled in the
PREDIMED-NAVARRA trial were randomly allocated to
one of three diets: two MedDiets (supplemented with either
extra-virgin olive oil or nuts) or a low-fat diet. They were
evaluated with the Mini-Mental State Examination
(MMSE) and the Clock Drawing Test (CDT) after
6.5 years of intervention. Subjects were genotyped for
CR1-rs3818361, CLU-rs11136000, PICALM-rs3851179
and Apolipoprotein E (ApoE) genes. We studied MedDiet–
gene interactions for cognition and assessed the effect of
the MedDiet on cognition across different genetic profiles.
A significant interaction (p = 0.041) between CLU-
rs11136000 and the MedDiet intervention on the MMSE
was found with a beneficial effect of MedDiet among
carriers of the T minor allele (B = 0.97, 95 % CI
0.45–1.49). Similar effect was observed for CR1-
rs3818361, but no significant interaction was observed
(p = 0.335). For PICALM-rs3851179, the MedDiet inter-
vention showed a beneficial effect in both genotype groups.
No apparent interaction was found for the CDT between
intervention and gene variants. Similarly, participants
randomly allocated to MedDiet groups, with favorable
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profiles of CR1, CLU and PICALM genes, significantly
improved CDT scores compared to controls with the same
genetic profile. Cognitive performance was better for non-
ApoE4 and for ApoE4 carriers of MedDiet groups com-
pared to controls, but for CDT performance, we only found
statistical significant differences for non-ApoE4 carriers.
A MedDiet intervention modulates the effect of genetic
factors on cognition. The effect of MedDiet might be
greater for subjects with a more favorable genetic profile.
Keywords Mediterranean diet  Cognition  CLU  CR1 
PICALM  APOE
Introduction
More than 35.6 million people were living with dementia
worldwide in 2010 (Prince et al. 2013). Due to the increased
life-expectancy, worldwide prevalence of dementia is pro-
jected to be 115.4 million in 2050 (Prince et al. 2013). Alz-
heimer0s disease (AD), vascular dementia (VD) and a mixed
neurodegenerative–vascular dementia are the most common
types of dementia (Jellinger and Attems 2010). There is not
cure for dementia. Vascular dementia can be delayed or even
prevented by treatment or management of the predisposing
vascular factors (Chang-Quan et al. 2011; Exalto et al. 2012),
but currently, there is no available treatment for delaying the
onset or the progression of Alzheimer disease. Moreover, the
only dementia with specific therapies is the dementia caused
by Alzheimer0s Disease, and these treatments offer only
symptomatic relief (Birks 2006; McShane et al. 2006). Thus,
dementia is a public health priority, and prevention is an
essential strategy to deal with it.
Apolipoprotein E (ApoE) is the most important suscepti-
bility locus for late-onset AD (Burke and Roses 1991), and it
has been also related to a higher risk of VD (Liu et al. 2012;
Yin et al. 2012). Most recently, genome-wide association
studies (GWAS) have identified single nucleotide polymor-
phisms (SNPs) at the CLU, CR1 and PICALM loci that
increase the risk of late-onset AD (Harold et al. 2009;
Lambert et al. 2009). A higher educational level and higher
engagement in physical, cognitive and social activities are
lifestyle factors that may reduce the risk of dementia or
cognitive decline (Hamer and Chida 2009; Kareholt et al.
2011; Morgan et al. 2012; Niti et al. 2008; Sattler et al.
2012). Nutritional epidemiology has examined the potential
benefit on cognition of fatty acids (van Gelder et al. 2007),
vitamins (Mangialasche et al. 2010; Tangney et al. 2009),
fish (van Gelder et al. 2007), fruit and vegetables (Hughes
et al. 2010) with favorable but not fully consistent results.
Thus, both genetic and lifestyle-related factors are involved
in cognitive decline and dementia, but these factors do not
contribute independently to neurodegeneration. In fact, the
development and also the phenotype of neurodegenerative
processes are a result of complex gene–environment inter-
actions. The interaction between ApoE genotype and physi-
cal and cognitive activities (Niti et al. 2008) and some
nutrients (Barberger-Gateau et al. 2007) has been examined
with conflicting results.
Over the last few years, interest in overall dietary patterns
has risen to a level comparable to the interest in nutrients and
foods. The Mediterranean diet (MedDiet) pattern is charac-
terized by olive oil as the main culinary fat, high intake of
plant-based, moderate-to-high consumption of fish and sea-
food, moderate-to-low intake of dairy products, low intake of
meat or meat products and regular but moderate intake of red
wine during meals (Willett et al. 1995). Compelling evidence
worldwide supports a benefit effect of this emerging nutri-
tional pattern on health (Roman et al. 2008). The MedDiet has
provided favorable results on cognitive function, cognitive
decline and dementia prevention along several observational
studies (Scarmeas et al. 2006; Psaltopoulou et al. 2008; Gu
et al. 2010; Feart et al. 2009; Scarmeas et al. 2009a, b; Roberts
et al. 2010; Tangney et al. 2011; Kesse-Guyot et al. 2013;
Samieri et al. 2013; Tsivgoulis et al. 2013). Recently, the
PREDIMED-NAVARRA primary prevention trial has con-
firmed the benefit on cognitive function and mild cognitive
impairment development (MCI) of a nutritional intervention
with MedDiet supplemented with extra-virgin olive oil
(EVOO) or nuts compared with a low-fat control diet (Mar-
tinez-Lapiscina et al. 2013a, b). However, MedDiet–gene
interactions have not been broadly evaluated in observational
studies, and when they were assessed, this assessment only
included populations outside of the Mediterranean basin, only
evaluated ApoE4 genotypes, and the results were negative
(Cherbuin and Anstey 2012; Roberts et al. 2010). To our
knowledge, no previous study has ever assessed gene–diet
interactions on cognition in the context of a long-term trial,
where subjects were randomly allocated to dietary patterns.
In our study, we aimed to explore the effect of an
intervention with MedDiet on cognitive function of par-
ticipants included in the PREDIMED-NAVARRA ran-
domized trial across different genetic variants not only of
ApoE, but also of the CLU, CR1 and PICALM genotypes,
previously identified as related to cognitive decline through
GWAS studies.
Methods
Trial design
The PREDIMED (PREvencio´n con DIeta MEDiterra´nea)
study was a randomized, parallel-group, vascular primary
prevention trial conducted in Spain from October 2003 to
December 2010 testing two interventions with MedDiet
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(supplemented with EVOO or with mixed nuts) versus a
control group advised to follow low-fat diet for outcomes on
cardiovascular disease events in a high-risk population. The
design and methods of the PREDIMED trial have been
described in detail elsewhere (Martinez-Gonzalez et al.
2012a). On July 2011, the Data Safety Monitoring Board
recommended stopping the trial since the pre-specified
stopping boundary for the benefit of the MedDiets on the
primary end point had been reached. The primary results
have been recently published (Estruch et al. 2013). No rel-
evant diet-related adverse effects were reported (Estruch
et al. 2013). The study population was drawn from 1 of 11
recruitment centers (PREDIMED-NAVARRA). At this site,
recruitment was completed by 2005, offering thus a longer
intervention and follow-up period than other centers.
Study population
Participants were community-dwelling men (55–80 years)
and women (60–80 years), without cardiovascular disease
(CVD) at baseline but at high vascular risk. The inclusion
criteria were the presence of either type-2 diabetes or at
least three major risk factors: current smoking, hyperten-
sion, dyslipidemia, overweight or family history of pre-
mature coronary heart disease. The presence of prior
history of CVD, any severe chronic condition or illiteracy
was considered as an exclusion criterion (Martinez-Gonz-
alez et al. 2012a). All procedures followed the Declaration
of Helsinki. The Institutional Review Board of the Navarra
recruitment center approved the study protocol (protocol
50/2005). All participants signed an informed consent. The
PREDIMED-NAVARRA center recruited 1,055 partici-
pants between 2003 and 2005.
The cognitive study was conducted over 8 months in the
primary care centers in the same day that the nurse per-
formed the blood analyses or the dietitians administered the
group or individual sessions for the PREDIMED trial. This
routine provides the participants the opportunity to com-
plete different task of the PREDIMED study on the same
day and promotes compliance. Participants who did not
Assessed for eligibility (n=1787)
Randomized (n=1055)
Allocated to Low-Fat diet Allocated to MedDiet+NutsAllocated to MedDiet+EVOO
Analyzed Analyzed Analyzed
Excluded (n= 732)
¨   Not meeting inclusion criteria (n= 7)
¨   Declined to participate (n=  725)
Enrollment 
(352)
Allocation
(352)(351)
Lost to follow-up
Deceased (27)
Not elegible (87)
(224)
Lost to follow-up
Deceased (29)
Lost to follow-up
Deceased (30)
Not elegible (117)
Declined to participate (40)
Not elegible (130)
Declined to participate (60)
(166) (132)
Follow-Up
Analysis
Declined to participate (13)
Fig. 1 Flowchart of participants
Genes Nutr (2014) 9:393 Page 3 of 13 393
123
attend the visits on their scheduled days were considered
non-eligible for the cognitive study. Those who attended
the visits but did not accept undergoing the neuropsycho-
logical study were excluded. Finally, 522 subjects accepted
to participate among 969 participants who were alive at the
moment of the cognitive evaluation (Fig. 1).
Nutrition interventions and dietary assessment
A nutritional intervention promoting the MedDiet or
advising to follow a lower fat diet was implemented among
participants allocated to the two MedDiet groups or control
group, respectively. At inclusion and quarterly thereafter,
dietitians administrated individual and group sessions,
separately for each group to provide an intensive education
to follow the intended intervention. Additionally, partici-
pants allocated the MedDiet groups received free allot-
ments of either EVOO (1 l/week) or 30 g/day of raw,
unprocessed mixed nuts (15 g walnuts, 7.5 g almonds and
7.5 g hazelnuts). Non-food gifts were provided to the
control group to improve compliance. Energy restriction
was not advised, nor physical activity promoted (Martinez-
Gonzalez et al. 2012a; Zazpe et al. 2008).
At baseline and yearly thereafter, a trained dietitian
administered a validated 137-item food-frequency ques-
tionnaire and a 14-item short questionnaire of adherence to
the MedDiet in a face-to-face interview. Both question-
naires have been validated (Fernandez-Ballart et al. 2010;
Martinez-Gonzalez et al. 2012b).
Cognitive assessment
Two brief cognitive tests were administered after a mean
follow-up of 6.5 years: the Mini-Mental State Examination
(MMSE) and the Clock Drawing Test (CDT). MMSE
evaluates orientation, registration, calculation, immediate
and differed verbal recall, language and visual construc-
tion. MMSE ranges from 0 to 30 (Folstein et al. 1975).
There is a validated Spanish version (Blesa et al. 2001).
The CDT is especially useful for assessing executive
function and visuospatial skills that are under-evaluated in
the MMSE (Freedman et al. 1994). We used a validated
Spanish version ranging from 0 to 7 (del Ser Quijano et al.
2004). Both cognitive tests are valid indicators of cognitive
impairment (Crook et al. 1986; Paganini-Hill and Clark
2011). Researchers who assessed the outcome were blinded
to group assignment.
Genotyping
CR1, CLU and PICALM genotyping was performed for
subjects included in the NAVARRA recruitment center of
the PREDIMED trial. DNA was extracted from overnight
fasting venous blood samples, collected in EDTA added
tubes. A commercial kit (Master PureTM; Epicentre,
Madison, WI, USA) was used to extract DNA from the
buffy coat fraction. All the subjects were genotyped for the
rs3818361 of the CR1 gene, rs11136000 of CLU gene and
rs3851179 of PICALM gene using Taqman with allele-
specific probes on the ABI Prism 7300HT Sequence
Detection System (Applied Biosystems, Foster City, CA,
USA) according to standardized laboratory protocols.
ApoE genotyping was carried out blind at the Genetic
and Molecular Epidemiology Unit, Valencia, Spain, for all
participants of the PREDIMED trial. Genomic DNA was
extracted from buffy coat with the MagNaPure LC DNA
Isolation Kit (Roche Diagnostics, Mannheim, Germany).
ApoE genotyping was carried out by a validated single-tube
protocol using fluorescent probes in the LightTyper
instrument (Roche), as previously reported (Frances et al.
2008). Quality control procedures including positive and
negative controls as well as replication of a random 15 %
of samples were applied. The duplicate concordance rate
was higher than 98 %.
Covariate assessment
The baseline general questionnaire provided information
about socio-demographic, lifestyle features and health-
related conditions and family history of cognitive impair-
ment or dementia (Martinez-Gonzalez et al. 2012a).
Anthropometric measurements were performed by standard
methods, as previously described (Martinez-Gonzalez et al.
2012a). Physical activity was assessed with the validated
Spanish version of the Minnesota Leisure-Time Physical
Activity questionnaire and expressed in minutes at a given
metabolic equivalent per day (MET-min/day) (Elosua et al.
1994, 2000).
Statistical analyses
Hardy–Weinberg equilibrium was tested using a chi-square
test. First, we explored differences in baseline character-
istics of participants according to the allocated intervention
groups. The association between the genotypes and cog-
nitive tests (MMSE and CDT) according to the intervention
groups (MedDiet groups vs. control group) were analyzed
using linear regression models after adjusting for con-
founding variables: age (years), sex, education (years of
formal education), ApoE genotype, family history of cog-
nitive impairment or dementia, hypertension, dyslipidemia,
type-2 diabetes mellitus, smoking status, alcohol intake (g/
day), body mass index (BMI) (kg/m2), total energy intake
(kcal/day) and physical activity (MET-min/day). Interac-
tion terms were not included in the models. Individual
models, one for each SNP (CLU, CR1 and PICALM) and
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for the ApoE genotype, were fitted. Interactions between
gene variants (dominant models) and the intervention
groups (MedDiet groups vs. control group) were estimated
with the likelihood ratio test in separated models for each
SNPs and adjusted for sex, age, education, ApoE genotype
(when pertinent), family history of cognitive impairment or
dementia and BMI. The false discovery rate method from
Benjamini and Hochberg was used to control for multiple
testing in the subgroups analysis (Benjamini and Hochberg
1995). Values in the text are means and SDs unless
otherwise indicated. All p values were two-tailed at the
\0.05 level. Statistical analyses were performed with
STATA version 12.0 software.
Results
In our population, the frequencies of these three SNPs did
fulfill the Hardy–Weinberg equilibrium (Table 1).
Anthropometric and lifestyle baseline features of partici-
pants of the PREDIMED-NAVARRA study according to
the intervention group are displayed in Table 2. As
expected from the randomized design, the groups were well
balanced with respect to all these baseline characteristics.
Since we evaluated the effect of MedDiet as a whole die-
tary pattern, we have merged participants of MedDi-
et ? EVOO and MedDiet ? Nuts groups in a single
MedDiet intervention group to compare this intervention
fostering adherence to the MedDiet pattern to a low-fat
intervention of control group.
As shown in Tables 3 and 4, we did not find statistically
significant differences in cognitive function scores (MMSE
and CDT) across the considered genetic variants. Never-
theless, the MedDiet intervention seemed to modulate the
effect of these genetic variants. In Table 3, the likelihood
ratio test showed a statistically significant interaction
between the CLU gene rs11136000 variant and the inter-
vention status for the MMSE test (p = 0.041). For this
SNP, we observed a beneficial effect of the MedDiet on
MMSE score among subjects carrying the T minor allele
(with a previously described protective effect). For these
participants, in those carrying at least one copy of the T
minor allele, the intervention with the MedDiet was asso-
ciated with an increase in 0.97 points of the MMSE score
(B = 0.97, 95 % CI 0.45–1.49, p \ 0.001). This observa-
tion remained statistically significant after the Benjamini–
Hochberg multiple comparison analysis. This effect was
not observed for those without the T minor allele
(B = 0.18, 95 % CI -0.52 to 0.88, p = 0.612). A similar
effect was observed for the CR1 gene rs3818361 variant,
even if in this case, the likelihood ratio test did not show a
statistically significant interaction (p = 0.335). Within this
frame, the MedDiet intervention significantly improved the
cognitive function measured by MMSE, 0.76 points, in
those subjects without the A minor risk allele (B = 0.76,
95 % CI 0.32–1.20, p = 0.001). No significant interaction
was observed between the PICALM gene rs3851179
polymorphisms (p = 0.872); however, when stratifying
our population according to the dominant model, we
observed a beneficial effect of the MedDiet intervention in
both genotype groups, in subjects without the T minor
allele (protective allele) and in subjects bearing at least one
T allele (B = 0.76, 95 % CI 0.10–1.43, p = 0.024 and
B = 0.51, 95 % CI 0.01–1.00, p = 0.046, respectively).
However, this observation did not remain statistically sig-
nificant after the Benjamini–Hochberg multiple compari-
son correction.
Table 4 shows similar analyses for the CDT. In this
case, no interaction was found between the MedDiet
intervention and any of these gene variants. However,
differences between genotype groups were found. For the
CLU gene rs11136000 variant, among subjects with the T
minor allele, MedDiet intervention significantly improved
CDT scores in 0.60 points (B = 0.60, 95 % CI 0.24–0.96,
p = 0.001). Similar effects were observed for the CR1
gene rs3818361 variant within subjects without the A risk
allele (B = 0.46, 95 % CI 0.13–0.79, p = 0.006) and for
the PICALM gene rs3851179 polymorphism. For this SNP,
Table 1 Genomic characteristics of the SNP markers used in the analysis
Gene_chr-band SNPs bp Alleles MA MAF p for Hardy–Weinberg
equilibrium*
OR 95 % CI
CLU_8p21.1 rs11136000 27,520,436 C/T T 0.4 0.84 0.86 0.81–0.90
CR1_1q32.2 rs3818361 205,758,672 G/A A 0.2 0.77 1.21 1.14–1.29
PICALM_11q14.2 rs3851179 85,546,288 C/T T 0.37 0.12 0.86 0.81–0.92
The PREDIMED-NAVARRA cognitive study
SNP single nucleotide polymorphisms, bp base pair physical position from the March 2006 human reference sequence (NCBI Build 36.1)
produced by the International Human Genome Sequencing Consortium, MA allele with the minimum frequency, MAF minimum allele
frequency, OR odd ratios, 95 % CI 95 % confidence interval
* Chi-square test for testing the Hardy–Weinberg equilibrium in the PREDIMED-NAVARRA study population
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subjects with at least one T minor allele with a probable
protective effect on cognition benefited from the MedDiet
intervention and their score in the CDT was significantly
increased in 0.59 points (B = 0.59, 95 % CI 0.18–1.00,
p = 0.005). All these observations remained statistically
significant after the Benjamini–Hochberg multiple com-
parison correction.
Finally, Table 5 displays the effects of the MedDiet
intervention on cognition (MMSE and CDT) in our popu-
lation according to the ApoE genotype. In the first general
analysis, the linear regression model revealed that E4 iso-
form was associated with a significantly decreased score
for both cognitive tests, MMSE (B = -0.96, 95 % CI
-1.47 to -0.45, p \ 0.001) and CDT (B = -0.50, 95 %
CI -0.87 to -0.14, p = 0.007). Interestingly, when strat-
ifying our subjects accordingly to their genotype for
ApoE4, we observed that the MedDiet intervention had a
protective effect on cognitive function for both non-ApoE4
and ApoE4 carriers. For the MMSE score, we found sta-
tistically differences in participants allocated to the Med-
Diet intervention among non-ApoE4 carriers. The MedDiet
intervention was associated with a 0.56-point higher
average MMSE score (B = 0.56 95 % CI 0.15–0.97,
p = 0.007). Specifically, in those carrying the E4 risk
isoform, the MedDiet was associated with an increased
score in more than 1.6 points (B = 1.61, 95 % CI
0.10–3.13, p = 0.037). However, this observation did not
remain statistically significant after de Benjamini–Hoch-
berg multiple comparison correction. A higher CDT score
was also found among subjects randomly allocated to the
MedDiet intervention, but this difference was only signif-
icant for non-ApoE4 carriers (B = 0.55, 95 % CI
0.25–0.85, p \ 0.001).
Discussion
In this study, an intervention with a MedDiet modulated
the association of genetic risk factors on cognition. The
interaction between MedDiet and the CLU gene
rs11136000 variant is a novel finding. Overall, the pro-
tective effect on cognition of an intervention with MedDiet
was greater in participants with a favorable genetic profile
of the CR1 gene (without A minor allele of the rs3818361);
the CLU gene (with T minor allele of the rs11136000); and
the PICALM gene (with T minor allele of the rs3851179).
The only exception was the higher CDT score found in
participants without the T minor protective allele of the
rs3851179 polymorphism of the PICALM gene compared
to those with the T minor allele of this polymorphism.
Considering the ApoE genotype, a MedDiet intervention
benefited both non-ApoE4 and ApoE4 carriers. Our results
strongly suggest a MedDiet effect on both MMSE and CDT
assessments among non-ApoE4 carriers, but the relatively
low number of ApoE4 carriers in our study hinders definite
conclusions regarding this group.
For more than 20 years, it has been known that ApoE4
genotype is a genetic risk factor for Alzheimer’s disease
Table 2 Baseline
characteristics of the
participants according to
intervention group
Data are shown as mean (SD)
unless otherwise stated
The PREDIMED-NAVARRA
trial
MAF minor allele frequency,
MedDiet Score Mediterranean
diet score
MedDiet ? EVOO MedDiet ? nuts Control (low-fat diet)
n 220 161 129
Male (%) 46 42 45
Age at baseline (years) 67 (6) 67 (6) 67 (6)
Hypertension (%) 77.3 82.6 81.4
Dyslipidemia (%) 70.5 69.6 66.7
Diabetes (%) 37.7 36.0 27.1
ApoE4 genotype (%) 13.6 15.1 15.6
CLU (rs11136000) MAF (%) 0.37 0.37 0.39
CR1 (rs3818361) MAF (%) 0.17 0.11 0.14
PICALM (3851179) MAF (%) 0.39 0.30 0.34
Education (years) 8.5 (2.8) 8.4 (2.9) 8.5 (3.4)
Family history of cognitive decline (%) 15.9 13.04 14.7
Body mass index (kg/m2) 29.3 (3.4) 28.9 (3.2) 29.0 (3.4)
Physical activity (MET-min/day) 283 (199) 279 (196) 252 (198)
Smoking status (%)
Current smoker 15 12 19
Former smoker 21 22 22
Energy intake (kcal/d) 2,272 (538) 2,263 (490) 2,190 (516)
Alcohol intake (g/day) 14 (21) 13 (18) 11 (18)
MedDiet Score 9.3 (1.8) 9.5 (1.8) 8.6 (1.9)
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(Burke and Roses 1991). Years later, GWAS studies
identified variants at other genes such as CLU, PICALM
and CR1 as risk factors for Alzheimer’s disease (Lambert
et al. 2009; Harold et al. 2009). These results have been
confirmed in a meta-analysis (Jun et al. 2010). More
recently, some of these risk gene variants have been
associated with cognitive decline, more concretely with
poor memory performance in population-based studies
(Barral et al. 2012; Pedraza et al. 2013). Parallel with these
studies, there is accruing evidence about the benefits in
cognition of lifestyle-related habits such as physical and
cognitive and social activities (Hamer and Chida 2009;
Table 3 Multivariable-adjusted means and differences (95 % CI) for the association between each of the SNPs and cognitive assessment (Mini-
Mental State Examination) according to intervention status
Overall CLU (rs11136000) CLU (rs11136000)
CC (n = 198) CT/TT (n = 309)
Means (95 % CI) 27.72 (27.44 to 28.00) 27.93 (27.70 to 28.15)
Adj. diff. 0 (Ref.) ?0.21 (-0.16 to ?0.57)
p value 0.266
By intervention Control (n = 45) MedDietc (n = 153) Control (n = 83) MedDietc (n = 226)
Means (95 % CI) 27.56 (26.95 to 28.16) 27.74 (27.42 to 28.06) 27.23 (26.80 to 27.68) 28.20 (27.94 to 28.50)
B, Adj. diff. (95 % CI)a 0 (Ref.) 0.18 (-0.52 to 0.88) 0 (Ref.) 0.97 (0.45 to 1.49)
p value (MedDiet vs. control) 0.612 \0.001d
p for interactionb 0.041
Overall CR1 (rs3818361) CR1 (rs3818361)
GG (n = 375) GA/AA (n = 133)
Means (95 % CI) 27.88 (27.68 to 28.09) 27.75 (27.40 to 28.09)
Adj. differences 0 (Ref.) -0.13 (-0.54 to 0.27)
p value 0.516
By intervention Control (n = 97) MedDietc (n = 278) Control (n = 32) MedDietc (n = 101)
Means (95 % CI) 27.37 (26.99 to 27.75) 28.12 (27.90 to 28.34) 27.51 (26.68 to 28.34) 27.66 (27.21 to 28.12)
B, Adj. diff. (95 % CI)a 0 (Ref.) 0.76 (0.32 to 1.20) 0 (Ref.) 0.15 (-0.83 to 1.13)
p value (MedDiet vs. control) 0.001d 0.762
p for interactionb 0.335
Overall PICALM (rs3851179) PICALM (rs3851179)
CC (n = 256) CT/TT (n = 248)
Means (95 % CI) 27.70 (27.45 to 27.95) 27.98 (27.73 to 28.23)
Adj. differences 0 (Ref.) 0.28 (-0.08 to 0.64)
p value 0.128
By intervention Control (n = 60) MedDietc (n = 196) Control (n = 69) MedDietc (n = 179)
Means (95 % CI) 27.18 (26.61 to 27.75) 27.89 (27.58 to 28.20) 27.61 (27.19 to 28.03) 28.11 (27.86 to 28.37)
B, Adj. diff. (95 % CI)a 0 (Ref.) 0.76 (0.10 to 1.43) 0 (Ref.) 0.51 (0.01 to 1.00)
p value (MedDiet vs. control) 0.024 0.046
p for interactionb 0.872
a General linear models adjusted for sex, age, education, family history of cognitive impairment or dementia, ApoE genotype, hypertension,
dyslipidemia, diabetes, smoking status, alcohol intake, body mass index, physical activity and total energy intake. B represents the difference in
points with the reference group
b Likelihood ratio test: SNP (dominant model)*intervention status, adjusted for sex, age, education, ApoE genotype, family history of cognitive
decline and BMI (kg/m2)
c Intervention group gathers MedDiet intervention groups, MedDiet ? EVOO (extra-virgin olive oil) and MedDiet ? Nuts as it has been stated
in the methods
d p value \ 0.05 after Benjamini–Hochberg multiple comparison adjustment
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Kareholt et al. 2011; Morgan et al. 2012; Niti et al. 2008;
Sattler et al. 2012) and nutrition in terms of nutrients and
foods with conflicting results (Coley et al. 2008). Regard-
ing dietary patterns as a whole, a protective effect of
MedDiet on cognitive function (Kesse-Guyot et al. 2013),
cognitive decline (Tsivgoulis et al. 2013; Tangney et al.
2011; Feart et al. 2009; Scarmeas et al. 2006) and devel-
opment of mild cognitive impairment (Scarmeas et al.
2009b; Roberts et al. 2010) and dementia (Roberts et al.
2010; Gu et al. 2010; Scarmeas et al. 2006, 2009a, b) has
been found in several observational studies but not in other
cohort studies (Psaltopoulou et al. 2008; Samieri et al.
Table 4 Multivariable-adjusted means and differences (95 % CI) for the association between each of the SNPs and cognitive assessment (Clock
Drawing Test) according to intervention status
Overall CLU (rs11136000) CLU (rs11136000)
CC (n = 198) CT/TT (n = 309)
Means (95 % CI) 5.18 (4.98 to 5.38) 5.33 (5.17 to 5.49)
Adj. diff. 0 (Ref.) 0.15 (-0.11 to 0.41)
p value 0.265
By intervention Control (n = 45) MedDietc (n = 153) Control (n = 83) MedDietc (n = 226)
Means (95 % CI) 4.83 (4.39 to 5.21) 5.24 (5.01 to 5.48) 4.90 (4.60 to 5.21) 5.50 (5.32 to 5.69)
B, Adj. diff. (95 % CI)a 0 (Ref.) 0.40 (-0.11 to 0.92) 0 (Ref.) 0.60 (0.24 to 0.96)
p value (MedDiet vs. control) 0.126 0.001d
p for interactionb 0.366
Overall CR1 (rs3818361) CR1 (rs3818361)
GG (n = 375) GA/AA (n = 133)
Means (95 % CI) 5.28 (5.13 to 5.42) 5.26 (5.01 to 5.50)
Adj. differences 0 (Ref.) -0.02 (-0.30 to 0.27)
p value 0.900
By intervention Control (n = 97) MedDietc (n = 278) Control (n = 32) MedDietc (n = 101)
Means (95 % CI) 4.96 (4.68 to 5.25) 5.43 (5.26 to 5.59) 4.92 (4.40 to 5.45) 5.24 (4.95 to 5.53)
B, Adj. diff. (95 % CI)a 0 (Ref.) 0.46 (0.13 to 0.79) 0 (Ref.) 0.31 (-0.30 to 0.93)
p value (MedDiet vs. control) 0.006d 0.762
p for interactionb 0.841
Overall PICALM (rs3851179) PICALM (rs3851179)
CC (n = 256) CT/TT (n = 248)
Means (95 % CI) 5.35 (5.17 to 5.52) 5.21 (5.03 to 5.39)
Adj. differences 0 (Ref.) -0.14 (-0.39 to 0.11)
p value 0.275
By intervention Control (n = 60) MedDietc (n = 196) Control (n = 69) MedDietc (n = 179)
Means (95 % CI) 5.19 (4.84 to 5.54) 5.41 (5.22 to 5.60) 4.78 (4.43 to 5.13) 5.36 (5.15 to 5.58)
B, Adj. diff. (95 % CI)a 0 (Ref.) 0.27 (-0.13 to 0.68) 0 (Ref.) 0.59 (0.18 to 1.00)
p value (MedDiet vs. control) 0.186 0.005d
p for interactionb 0.133
a General linear models adjusted for sex, age, education, family history of cognitive impairment or dementia, ApoE genotype, hypertension,
dyslipidemia, diabetes, smoking status, alcohol intake, body mass index, physical activity and total energy intake. B represents the difference in
points with the reference group
b Likelihood ratio test: SNP (dominant model)*intervention status, adjusted for sex, age, education, ApoE genotype, family history of cognitive
decline and BMI (kg/m2)
c Intervention group gathers MedDiet intervention groups, MedDiet ? EVOO (extra-virgin olive oil) and MedDiet ? Nuts as it has been stated
in the methods
d p value \ 0.05 after Benjamini–Hochberg multiple comparison adjustment
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2013; Cherbuin and Anstey 2012). Thus, there is not
definitive evidence from observational studies to ensure the
benefits of an intervention with MedDiet against cognitive
impairment. However, a protective effect has been recently
suggested by the PREDIMED-NAVARRA randomized
trial conducted in Spain (Martinez-Lapiscina et al. 2013a,
b). This is important since some observational studies may
not find a protective association between the MedDiet and
cognitive function because their MedDiet-like dietary
pattern did not truly represent the traditional MedDiet due
to sociocultural factors (Cherbuin and Anstey 2012).
Nevertheless, the benefit of MedDiet on cognitive impair-
ment is far from being resolved. Going a step beyond, the
interaction between MedDiet and risk factors has been
poorly studied. In a study conducted in Australia, the
MedDiet did not show any protective association with
cognitive changes and no significant interaction was
observed for the ApoE4 genotype and the MedDiet
(Cherbuin and Anstey 2012). We did not identify any
studies assessing the interaction between MedDiet and
CR1, CLU and PICALM gene variants.
We acknowledge that our study may have some limi-
tations. First, cognitive function of participants was not
assessed at baseline. Nevertheless, the presence of any
chronic condition that may limit the compliance with the
protocol was an exclusion criterion, and this is a good
reason to confide that a relevant cognitive decline was not
present at baseline. In addition, the randomized design of
the trial resulted in well-balanced groups with respect to
the overall baseline features, and this argues for similar
cognitive status at baseline. Moreover, we performed our
analyses after adjusting for a wide range of potential
confounders. Second, the sample size was small. Third,
the study has a single blinded nature, but there is no
possibility of conducting true double-blind long-term tri-
als in nutrition. The selection of a low-fat dietary pattern
as comparator might have introduced a limitation in our
results, because of the potential protection afforded by
educating the control group on a low-fat diet. The role of
this dietary pattern on cognition is not completely
understood. Should the low-fat diet have a detrimental
effect, the allocation to a low-fat diet for comparison in
the control group may represent an alternative explanation
to the protective effect observed for the MedDiet. How-
ever, the long-term sustainability of low-fat diet is sub-
optimal, and in any case, controls may have experienced a
benefit from their education on a low-fat diet that would
have not existed should they have followed a Western-
type diet. Another limitation is that we evaluated the
interaction between MedDiet and gene risk variants in a
Table 5 Multivariable-adjusted means and differences (95 % CI) for the association between the SNPs and cognitive assessment according to
intervention status
Mini-Mental State Examination Clock Drawing Test
B (95 % CI)a p value p for interactionb B (95 % CI)a p value p for interactionb
APOE 0.665 0.091
E2 carriers (32) 0.44 (-0.29 to 1.17) 0.241 0.25 (-0.27 to 0.77) 0.348
E3/E3 (401) 0 (Ref.) 0 (Ref.)
E4 carriers (74) -0.96 (-1.47 to -0.45) \0.001d -0.50 (-0.87 to -0.14) 0.007d
Non-E4 carriers
Control (Low-fat diet) (108) 0 (Ref.) 0 (Ref.)
Intervention (MedDietc)
(325)
0.56 (0.15 to 0.97) 0.007d 0.55 (0.25 to 0.85) \0.001d
E4 carriers
Control (Low-fat diet) (20) 0 (Ref.) 0 (Ref.)
Intervention (MedDietc) (54) 1.61 (0.10 to 3.13) 0.037 0.33 (-0.60 to 1.27) 0.477
The numbers in parentheses are the subjects with this genotype
MMSE Mini-Mental State Examination, CDT Clock Drawing Test, Ref. Advert this is the reference group
a General linear models adjusted for sex, age, education, family history of cognitive impairment or dementia, hypertension, dyslipidemia,
diabetes, smoking status, alcohol intake, body mass index, physical activity and total energy intake. B represents the difference in points with the
reference group
b Likelihood ratio test: SNP (dominant model)*intervention status, adjusted for sex, age, education, ApoE genotype, family history of cognitive
decline and BMI (kg/m2)
c Intervention group gathers MedDiet intervention groups, MedDiet ? EVOO (extra-virgin olive oil) and MedDiet ? Nuts as it has been stated
in the methods
d p value \ 0.05 after Benjamini–Hochberg multiple comparison adjustment
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high-risk vascular population so generalization of our
findings to the average general population is uncertain.
Finally, we acknowledge that our results are relevant in
terms of statistical significance, but they do not represent
a large difference from the clinical or practical point of
view. However, we think that our manuscript is scientif-
ically relevant because it points to a biological interaction
between MedDiet and gene profile beyond ApoE. The
introduction of this interaction is a novelty, and our
exploratory results may favor further and deeper studies
of gene–nutrition interactions in larger cohorts that may
consider not only cognitive function but also, more
importantly, the incidence of clinical cases of mild cog-
nitive impairment or dementia.
Our study has also strengths. First, this is a long-term
randomized controlled trial with supplementation with
hallmark components of the traditional MedDiet such as
EVOO and nuts. Second, we included several potential
confounders in our analyses that help us to rule out residual
confounding.
In conclusion, we provide here, for the first time, the
evidence of an interaction between the MedDiet and
CLU on cognitive function in the context of a ran-
domized trial. A MedDiet intervention modulates the
effect of the genetic risk factors on cognition, and
overall, the protective effect of MedDiet may be greater
for subjects with favorable genetic profile. Future
research is needed to obtain firmed evidence of the
complex MedDiet–gene interaction.
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